The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 10, 2019

Filed:

Oct. 12, 2016
Applicant:

Woomera Therapeutics, Inc, Lebanon, NH (US);

Inventors:

William G. North, Hanover, NH (US);

Roy H. L. Pang, Etna, NH (US);

Assignee:

Woomera Therapeutics, Lebanon, NH (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 38/31 (2006.01); C07K 16/26 (2006.01); A61K 51/10 (2006.01); C07K 14/47 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); C07K 7/06 (2006.01); C07K 14/72 (2006.01); G01N 33/574 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2869 (2013.01); A61K 38/31 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 49/0058 (2013.01); A61K 51/1036 (2013.01); A61K 51/1063 (2013.01); A61K 51/1096 (2013.01); C07K 7/06 (2013.01); C07K 14/4703 (2013.01); C07K 14/72 (2013.01); C07K 16/26 (2013.01); G01N 33/57492 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/34 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01);
Abstract

Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V(e.g., AbnV), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.


Find Patent Forward Citations

Loading…